| Indicators | Browse All

Processa Pharmaceuticals, Inc. (PCSA)

Healthcare | Biotechnology | Vero Beach, United States | NasdaqCM
1.81 USD -0.09 (-4.737%) ⇩ (Oct. 13, 2026, 1:27 p.m. EDT)

Short-term:★☆☆☆☆Long-term:⯪☆☆☆☆Dividends:☆☆☆☆☆
Hot Take ↕ | Oct. 10, 2026, 3:41 a.m. EDT

The immediate outlook is severely clouded by a relentless downward price trend and deteriorating financial health. Over the last four consecutive years, the stock has lost nearly 99.9% of its value, signaling a profound structural collapse rather than a temporary setback. Fundamentally, the company is bleeding cash with negative free cash flow and a negative book value, indicating that the equity is technically underwater. While recent headlines highlight strategic acquisitions and potential funding rounds, these are desperate attempts to sustain operations rather than indicators of a turnaround. The lack of any dividend history confirms the company is in a pure survival mode. For investors, the risk of permanent capital loss outweighs any speculative hope of a recovery, making this a clear avoidance candidate.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoARIMA ✓0.209962
MSTL0.212122
AutoTheta0.220217
AutoETS0.220251

Forecast horizon: 45 days | Selected: AutoARIMA

Forecast Reliability
Score 26%
H-stat 4.56
Ljung-Box p 0.000
Jarque-Bera p 0.009
Excess Kurtosis 0.86
Attribute Value
Sector Healthcare
Market Cap 5,064,767
Forward P/E -0.48
Beta 1.20
Website https://www.processapharmaceuticals.com

Info Dump

Attribute Value
52 Week Change -0.8080808
Address1 601 21st Street
Address2 Suite 300
All Time High 67,375.0
All Time Low 1.041
Ask 1.5
Ask Size 11
Average Daily Volume10 Day 359,510
Average Daily Volume3 Month 275,571
Average Volume 275,571
Average Volume10Days 359,510
Beta 1.197
Bid 1.13
Bid Size 2
Book Value -0.114
City Vero Beach
Compensation As Of Epoch Date 1,767,139,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 1.81
Current Ratio 0.866
Custom Price Alert Confidence HIGH
Date Short Interest 1,790,726,400
Day High 1.93
Day Low 1.8
Display Name Processa Pharmaceuticals
Dividend Date 1,577,059,200
Dividend Yield 0.0
Earnings Timestamp End 1,755,288,000
Earnings Timestamp Start 1,754,942,400
Ebitda -12,856,880
Ebitda Margins 0.0
Enterprise To Ebitda -0.398
Enterprise Value 5,111,108
Eps Forward -3.75
Eps Trailing Twelve Months -4.33
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 15
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fax 443 288 4420
Fifty Day Average 2.00404
Fifty Day Average Change -0.19404006
Fifty Day Average Change Percent -0.096824445
Fifty Two Week Change Percent -80.80808
Fifty Two Week High 11.0
Fifty Two Week High Change -9.190001
Fifty Two Week High Change Percent -0.8354546
Fifty Two Week Low 1.041
Fifty Two Week Low Change 0.76899993
Fifty Two Week Low Change Percent 0.7387127
Fifty Two Week Range 1.041 - 11.0
Financial Currency USD
First Trade Date Milliseconds 1,394,202,600,000
Float Shares 2,709,417
Forward Eps -3.75
Forward P E -0.48266664
Free Cashflow -8,735,363
Full Exchange Name NasdaqCM
Full Time Employees 12
Fullday Change -0.09000003
Fullday Change Percent -4.736844
Fullday Price 1.81
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Has Pre Post Market Data 1
Held Percent Insiders 0.14823
Held Percent Institutions 0.18697001
Implied Shares Outstanding 2,798,214
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Last Split Date 1,765,929,600
Last Split Factor 1:25
Long Business Summary Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells. Its oncology pipeline includes NGC-Cap (PCS6422), a combination of PCS6422 and capecitabine, which is in a Phase 2 clinical trial to treat metastatic breast, colorectal, hepatocellular, pancreatic, gastric, and other solid tumors; and NGC-Iri (PCS11T), an analog of an active metabolite of irinotecan, which is in preclinical trials to treat lung, pancreatic, ovarian, colorectal, gastric, cervical, and other cancers. The company also develops non-oncology drugs consisting of PCS499, an oral tablet of the deuterated analog of pentoxifylline that has completed a Phase 2b clinical trial for the treatment of primary glomerular diseases, including focal segmental glomerulosclerosis (FSGS), IgA, and membranous nephropathy, as well as ulcerative necrobiosis lipoidica; and PCS12852, a highly specific and potent 5HT4 agonist that has completed a Phase 2 clinical trial for the treatment of gastroparesis and constipation disorders. It has license agreements with Elion Oncology, Inc., Aposense, Ltd., Yuhan Corporation, and Sun Pharmaceuticals Industries Limited. Processa Pharmaceuticals, Inc. was founded in 2015 and is based in Vero Beach, Florida.
Long Name Processa Pharmaceuticals, Inc.
Market us_market
Market Cap 5,064,767
Market State REGULAR
Max Age 86,400
Message Board Id finmb_531045531
Most Recent Quarter 1,782,777,600
Net Income To Common -13,438,184
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 5,279,499
Open 1.93
Operating Cashflow -11,971,522
Operating Margins 0.0
Payout Ratio 0.0
Phone 772 453 2899
Previous Close 1.9
Price Hint 4
Price To Book -15.8771925
Profit Margins 0.0
Quick Ratio 0.082
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change -0.09000003
Regular Market Change Percent -4.736844
Regular Market Day High 1.93
Regular Market Day Low 1.8
Regular Market Day Range 1.8 - 1.93
Regular Market Open 1.93
Regular Market Previous Close 1.9
Regular Market Price 1.81
Regular Market Time 1,791,912,469
Regular Market Volume 44,648
Return On Assets -1.56785
Return On Equity -4.6419697
Sand P52 Week Change 0.17502642
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 2,798,214
Shares Percent Shares Out 0.0015
Shares Short 4,140
Shares Short Previous Month Date 1,788,134,400
Shares Short Prior Month 35,949
Short Name Processa Pharmaceuticals, Inc.
Short Percent Of Float 0.0017
Short Ratio 0.16
Source Interval 15
State FL
Symbol PCSA
Total Cash 196,325
Total Cash Per Share 0.07
Total Debt 0
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -4.33
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 2.468475
Two Hundred Day Average Change -0.65847516
Two Hundred Day Average Change Percent -0.26675382
Type Disp Equity
Volume 44,648
Website https://www.processapharmaceuticals.com
Zip 32,960